2018 Section 5 - Rhinology and Allergic Disorders

Medical management of AFRS

sinusitis. Otolaryngol Head Neck Surg . 2001;125: 487–490. 69. Greenhaw B, de Shazo RD, Arnold J, Wright L. Fungal immunotherapy in patients with allergic fungal sinusi- tis. Ann Allergy Asthma Immunol . 2011;107:432– 436. 70. Mabry RL, Manning SC, Mabry CS. Immunotherapy in the treatment of allergic fungal sinusitis. Otolaryn- gol Head Neck Surg . 1997;116:31–35. 71. Mabry RL, Mabry CS. Immunotherapy for allergic fungal sinusitis: the second year. Otolaryngol Head Neck Surg . 1997;117:367–371. 72. Mabry RL, Marple BF, Folker RJ, Mabry CS. Immunotherapy for allergic fungal sinusitis: three years’ experience. Otolaryngol Head Neck Surg . 1998;119:648–651. 73. Riccioni G, Di Ilio C, Conti P, Theoharides TC, D’Orazio N. Advances in therapy with antileukotriene drugs. Ann Clin Lab Sci . 2004;34:379–387. 74. Schubert MS. Allergic fungal sinusitis: pathogene- sis and management strategies. Drugs . 2004;64:363– 374. 75. Schubert MS. Antileukotriene therapy for allergic fun- gal sinusitis. J Allergy Clin Immunol . 2001;108:466– 467.

62. Calderon MA, Alves B, Jacobson M, Hurwitz B, Sheikh A, Durham S. Allergen injection immunother- apy for seasonal allergic rhinitis. Cochrane Database Syst Rev . 2007;(1):CD001936. 63. Wilson DR, Lima MT, Durham SR. Sublingual im- munotherapy for allergic rhinitis: systematic review and meta-analysis. Allergy . 2005;60:4–12. 64. Abramson MJ, Puy RM, Weiner JM. Is allergen im- munotherapy effective in asthma? A meta-analysis of randomized controlled trials. Am J Respir Crit Care Med. 1995;151:969–974. 65. Ross RN, Nelson HS, Finegold I. Effectiveness of specific immunotherapy in the treatment of asthma: a meta-analysis of prospective, randomized, double-blind, placebo-controlled studies. Clin Ther . 2000;22:329–341. 66. Abramson MJ, Puy RM, Weiner JM. Allergen im- munotherapy for asthma. Cochrane Database Syst Rev . 2003;(4):CD001186. 67. Folker RJ, Marple BF, Mabry RL, Mabry CS. Treat- ment of allergic fungal sinusitis: a comparison trial of postoperative immunotherapy with specific fungal antigens. Laryngoscope . 1998;108:1623–1627. 68. Bassichis BA, Marple BF, Mabry RL, Newcomer MT, Schwade ND. Use of immunotherapy in previously treated patients with allergic fungal

55. Rains BM 3rd, Mineck CW. Treatment of allergic fun- gal sinusitis with high-dose itraconazole. Am J Rhinol . 2003;17:1–8. 56. Cody DT 2nd, Neel HB 3rd, Ferreiro JA, Roberts GD. Allergic fungal sinusitis: the Mayo Clinic experi- ence. Laryngoscope . 1994;104:1074–1079. 57. Ferguson BJ. Eosinophilic mucin rhinosinusitis: a distinct clinicopathological entity. Laryngoscope . 2000;110(5 Pt 1):799–813. 58. Sabatelli F, Patel R, Mann PA, et al. In vitro activities of posaconazole, fluconazole, itraconazole, voricona- zole, and amphotericin B against a large collection of clinically important molds and yeasts. Antimicrob Agents Chemother . 2006;50:2009–2015. 59. Huang A, Govindaraj S. Topical therapy in the man- agement of chronic rhinosinusitis. Curr Opin Oto- laryngol Head Neck Surg . 2013;21:31–38. 60. Jen A, Kacker A, Huang C, Anand V. Fluconazole nasal spray in the treatment of allergic fungal sinusi- tis: a pilot study. Ear Nose Throat J . 2004;83:692, 694–695. 61. Brehler R, Klimek L, Kopp MV, Christian Vir- chow J. Specific immunotherapy-indications and mode of action. Dtsch Arztebl Int . 2013;110: 148–158.

International Forum of Allergy & Rhinology, Vol. 4, No. 9, September 2014

86